Medtronic PLC $MDT Shares Acquired by Stratos Wealth Partners LTD.

Key Points

• Stratos Wealth Partners LTD. increased its holdings in Medtronic PLC by 4.5% in the second quarter, owning 65,856 shares valued at $5,741,000.
• Medtronic recently reported $1.26 EPS for the quarter, exceeding estimates of $1.23, with a revenue of $8.58 billion, a 7.7% increase year-over-year.
• The company declared a quarterly dividend of $0.71, yielding 3.0%, with a payout ratio of 78.24% as of September 26th.

Stratos Wealth Partners LTD. increased its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 4.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,856 shares of the medical technology company's stock after acquiring an additional 2,859 shares during the quarter. Stratos Wealth Partners LTD.'s holdings in Medtronic were worth $5,741,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Brighton Jones LLC lifted its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. GAMMA Investing LLC increased its position in Medtronic by 41.1% in the first quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company's stock worth $1,427,000 after buying an additional 4,626 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Medtronic by 11.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 531,059 shares of the medical technology company's stock valued at $47,721,000 after buying an additional 53,340 shares during the last quarter. CWA Asset Management Group LLC boosted its holdings in shares of Medtronic by 38.1% during the first quarter. CWA Asset Management Group LLC now owns 7,941 shares of the medical technology company's stock valued at $714,000 after acquiring an additional 2,189 shares during the period. Finally, Advocate Group LLC boosted its holdings in shares of Medtronic by 3.0% during the first quarter. Advocate Group LLC now owns 110,031 shares of the medical technology company's stock valued at $9,887,000 after acquiring an additional 3,255 shares during the period. Institutional investors own 82.06% of the company's stock.

Insider Buying and Selling at Medtronic

In related news, Director William R. Jellison acquired 2,500 shares of Medtronic stock in a transaction dated Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director directly owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the business's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.26% of the company's stock.

Medtronic Trading Up 0.6%

Shares of Medtronic stock opened at $95.62 on Friday. The business has a fifty day simple moving average of $94.07 and a 200-day simple moving average of $88.98. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $99.37. The firm has a market cap of $122.65 billion, a price-to-earnings ratio of 26.34, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion for the quarter, compared to analysts' expectations of $8.37 billion. During the same period in the previous year, the business earned $1.23 earnings per share. Medtronic's revenue for the quarter was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were given a $0.71 dividend. The ex-dividend date was Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic's payout ratio is 78.24%.

Analysts Set New Price Targets

Several analysts recently weighed in on MDT shares. Weiss Ratings reiterated a "buy (b-)" rating on shares of Medtronic in a research report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on Medtronic from $98.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, August 20th. Wolfe Research raised Medtronic from an "underperform" rating to a "peer perform" rating in a report on Monday, June 30th. Sanford C. Bernstein lifted their target price on Medtronic from $97.00 to $98.00 and gave the company an "outperform" rating in a research note on Wednesday, August 20th. Finally, The Goldman Sachs Group reduced their price target on Medtronic from $82.00 to $81.00 and set a "sell" rating for the company in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $102.82.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.